☆ 4.7 Article

Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease

JOURNAL OF NEUROLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Effect of Amyloid on Cognitive Performance in Parkinson's Disease and Dementia with Lewy Bodies

Kyoungwon Baik et al.

Summary: This study investigated the effect of amyloid accumulation on cognitive dysfunction in patients with Parkinson's disease and dementia with Lewy bodies. The results showed that while the burden of amyloid was higher in the dementia with Lewy bodies group, amyloid accumulation was negatively associated with memory and language functions only in the Parkinson's disease group.

MOVEMENT DISORDERS (2023)

Add to Collection

Article Clinical Neurology

Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance

Alexa Pichet Binette et al.

Summary: This study found that creatinine and body mass index are associated with certain plasma biomarker levels, but they do not have clinically relevant confounding effects for the majority of individuals.

ALZHEIMERS & DEMENTIA (2023)

Add to Collection

Review Neurosciences

Cognitive heterogeneity in Parkinson's disease A mechanistic view

Marc Carceles-Cordon et al.

Summary: Cognitive impairment is a common feature in Parkinson's disease (PD) and affects patients, their caregivers, and the healthcare system significantly. This review summarizes the clinical landscape of cognition in PD and explores the development of cognitive impairment and dementia in relation to the spread of the pathological protein alpha-synuclein (aSyn). The Braak hypothesis suggests that aSyn spreads from brainstem regions to cortical regions responsible for higher cognitive functions. The review evaluates the Braak hypothesis from different perspectives and highlights the importance of individual host factors in the heterogeneity of cognitive decline in PD.

NEURON (2023)

Add to Collection

Review Clinical Neurology

Clinical trials for cognition in Parkinson's disease: Where are we and how can we do better?

Ece Bayram et al.

Summary: Cognitive impairment is common in Parkinson's disease (PD) and effective treatments beyond cholinesterase inhibitors are lacking. This study examined recent clinical trials for cognitive outcomes in PD and found that only a small proportion of trials were completed and few showed significant improvement. Factors contributing to the lack of detectable benefit include trial design, lack of enrichment for at-risk groups, short follow-up duration, and insensitive outcome measures.

PARKINSONISM & RELATED DISORDERS (2023)

Add to Collection

Article Clinical Neurology

Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease

Katheryn A. Q. Cousins et al.

Summary: This study found that plasma GFAP may be sensitive to concomitant AD pathology in LBSD, especially accumulation of beta-amyloid plaques.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

Add to Collection

Article Neurosciences

Head-to-head comparison of 6 plasma biomarkers in early multiple system atrophy

Yu Guo et al.

Summary: There is an urgent need for reliable biomarkers to diagnose multiple system atrophy (MSA) early and accurately. This study compared plasma biomarkers in distinguishing MSA from its mimics and healthy controls, and evaluated their performance in detecting disease severity and brain atrophy. Plasma neurofilament light (NfL) was found to be the most effective biomarker in distinguishing MSA from controls. GFAP and A beta 40 showed promise in distinguishing MSA-C and MSA-P from their respective mimics. Combining plasma markers improved discriminatory efficacy. Higher levels of GFAP and NfL were associated with brain atrophy and disease severity in MSA patients.

NPJ PARKINSONS DISEASE (2023)

Add to Collection

Article Neurosciences

Plasma GFAP in Parkinson's disease with cognitive impairment and its potential to predict conversion to dementia

Yilin Tang et al.

Summary: The levels of plasma GFAP were measured in PD patients with normal cognition, mild cognitive impairment (PD-MCI), dementia (PDD), and healthy controls. The results showed that plasma GFAP levels were elevated in PDD and PD-MCI patients compared to healthy controls, and were negatively correlated with MMSE score in PD participants. Plasma GFAP was found to have potential value in distinguishing PDD patients and predicting MCI-to-dementia conversion in PD, with higher accuracy than NfL, Tau, and pTau181.

NPJ PARKINSONS DISEASE (2023)

Add to Collection

Article Neurosciences

A Panel of Plasma Biomarkers for Differential Diagnosis of Parkinsonian Syndromes

Qi Li et al.

Summary: The aim of this study was to explore the most reliable panel of plasma biomarkers for differential diagnosis of parkinsonian syndromes. The results showed that different combinations of plasma biomarkers have high diagnostic value in distinguishing different parkinsonian syndromes from healthy controls. Plasma NfL may have added value to the blood-based biomarker panel for differentiating parkinsonian syndromes.

FRONTIERS IN NEUROSCIENCE (2022)

Add to Collection

Article Clinical Neurology

Proteinopathy and Longitudinal Cognitive Decline in Parkinson Disease

Peter S. Myers et al.

Summary: This study found that the accumulation or risk of beta-amyloid is closely related to cognitive decline and the onset of dementia in Parkinson's disease patients. This suggests that beta-amyloid may serve as a prognostic indicator and biomarker for cognitive changes in Parkinson's disease.

NEUROLOGY (2022)

Add to Collection

Article Neurosciences

Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders

Melek Firat Altay et al.

Summary: This study systematically investigates the astrocytic pathology of α-synuclein (aSyn) in Lewy body disorders (LBDs) and in multiple system atrophy (MSA). The findings suggest that astrocytic aSyn accumulations represent a major part of aSyn pathology in LBDs and possess a distinct sequence and post-translational modification (PTM) signature. This study provides insights into the diversity of aSyn pathology in different cell types and may lead to the identification of novel disease mechanisms and therapeutic targets.

ACTA NEUROPATHOLOGICA COMMUNICATIONS (2022)

Add to Collection

Article Clinical Neurology

Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease

Javier Pagonabarraga et al.

Summary: The study found that plasma NfL levels can be used to differentiate mild cognitive impairment in Parkinson's disease and predict future dementia progression.

PARKINSONISM & RELATED DISORDERS (2022)

Add to Collection

Review Clinical Neurology

Biofluid markers of blood-brain barrier disruption and neurodegeneration in Lewy body spectrum diseases: A systematic review and meta-analysis

Yuen Yan Wong et al.

Summary: This study provides evidence of blood-brain barrier dysfunction in Lewy body spectrum diseases. Patients with idiopathic Parkinson's disease (PD) and PD dementia (PDD) and/or dementia with Lewy bodies (DLB) have higher levels of cerebrospinal fluid to blood albumin ratio and blood neurofilament light chain, indicating BBB disruption and neurodegenerative co-pathology involvement. The severity of BBB breakdown is greater in Lewy body diseases with cognitive impairment.

PARKINSONISM & RELATED DISORDERS (2022)

Add to Collection

Article Neurosciences

Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson's disease

Lucia Batzu et al.

Summary: Early identification of cognitive impairment in Parkinson's disease has important implications. This study found that plasma NfL concentration is associated with cognitive performance in PD patients and may serve as a biomarker for cognitive progression.

NPJ PARKINSONS DISEASE (2022)

Add to Collection

Review Clinical Neurology

Frequency of dementia in Parkinson's disease: A systematic review and meta-analysis

Catarina Severiano E. Sousa et al.

Summary: This study conducted a systematic review to evaluate the frequency of Parkinson's disease dementia (PDD) reported in published studies. The results showed that approximately one-quarter of Parkinson's disease (PD) patients were diagnosed with PDD, and the frequency varied according to methodological, clinical, and demographic factors.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2022)

Add to Collection

Article Clinical Neurology

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease

Joana B. Pereira et al.

Summary: The study suggests that plasma GFAP concentration is associated with brain amyloid-beta pathology but not tau aggregation in Alzheimer's disease. This indicates that plasma GFAP may be incorporated into current hypothetical models of Alzheimer's disease pathogenesis and used as a non-invasive tool to detect early astrocytosis.

BRAIN (2021)

Add to Collection

Article Immunology

Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson's disease

Yongyun Zhu et al.

Summary: This study in China found a potential association between plasma neurofilament light chain levels and cognitive function in Parkinson's disease patients, with higher levels of NfL associated with increased cognitive impairment. Higher MMSE scores were correlated with lower plasma NfL levels in PD patients.

JOURNAL OF NEUROIMMUNOLOGY (2021)

Add to Collection

Article Clinical Neurology

Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease

Whitley W. Aamodt et al.

Summary: The study found that neurofilament light chain protein (NfL) is associated with cognitive function in Parkinson's disease (PD) patients and can predict future cognitive decline. Plasma NfL was identified as a useful prognostic biomarker for PD, predicting the likelihood of PD patients converting to mild cognitive impairment or dementia.

MOVEMENT DISORDERS (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Biomarkers for neurodegenerative diseases

Oskar Hansson

Summary: Biomarkers for neurodegenerative diseases play a crucial role in improving diagnostic workup and therapy monitoring, with emerging blood-based markers and discussions on their implementation in clinical practice and trials.

NATURE MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

A multicentre validation study of the diagnostic value of plasma neurofilament light

Nicholas J. Ashton et al.

Nature Communications (2021)

Add to Collection

Article Medicine, General & Internal

Parkinson disease-associated cognitive impairment

Dag Aarsland et al.

Summary: Cognitive impairment is common in Parkinson disease patients, with varying degrees of severity, emphasizing the importance of early identification and treatment.

NATURE REVIEWS DISEASE PRIMERS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia

Shorena Janelidze et al.

NATURE MEDICINE (2020)

Add to Collection

Article Geriatrics & Gerontology

Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson's Disease

Nai-Ching Chen et al.

FRONTIERS IN AGING NEUROSCIENCE (2020)

Add to Collection

Article Neurosciences

Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease

Adeline Su Lyn Ng et al.

MOLECULAR NEURODEGENERATION (2020)

Add to Collection

Article Neurosciences

Cognitive Function and Quality of Life in Parkinson's Disease: A Cross-Sectional Study

Yilin Tang et al.

JOURNAL OF PARKINSONS DISEASE (2020)

Add to Collection

Article Neurosciences

Neuroinflammation and protein pathology in Parkinson's disease dementia

Antonina Kouli et al.

ACTA NEUROPATHOLOGICA COMMUNICATIONS (2020)

Add to Collection

Letter Clinical Neurology

Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide

Sebastian Schade et al.

MOVEMENT DISORDERS CLINICAL PRACTICE (2020)

Add to Collection

Article Clinical Neurology

Serum NFL discriminates Parkinson disease from atypical parkinsonisms

Taina M. Marques et al.

NEUROLOGY (2019)

Add to Collection

Article Neurosciences

Clinical Correlates of Cerebral Amyloid Deposition in Parkinson's Disease Dementia: Evidence from a PET Study

Giovanni Palermo et al.

JOURNAL OF ALZHEIMERS DISEASE (2019)

Add to Collection

Article Clinical Neurology

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis

Suzanne E. Schindler et al.

NEUROLOGY (2019)

Add to Collection

Review Biochemistry & Molecular Biology

Astrocytic Oxidative/Nitrosative Stress Contributes to Parkinson's Disease Pathogenesis: The Dual Role of Reactive Astrocytes

Asha Rizor et al.

ANTIOXIDANTS (2019)

Add to Collection

Article Neurosciences

Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment

Patrick Oeckl et al.

JOURNAL OF ALZHEIMERS DISEASE (2019)

Add to Collection

Article Multidisciplinary Sciences

High performance plasma amyloid-β biomarkers for Alzheimer's disease

Akinori Nakamura et al.

NATURE (2018)

Add to Collection

Article Multidisciplinary Sciences

Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease

Yung-Shuan Lin et al.

SCIENTIFIC REPORTS (2018)

Add to Collection

Review Neurosciences

The Emerging Evidence of the Parkinson Pandemic

E. Ray Dorsey et al.

JOURNAL OF PARKINSONS DISEASE (2018)

Add to Collection

Article Genetics & Heredity

A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci

Diana Chang et al.

NATURE GENETICS (2017)

Add to Collection

Article Clinical Neurology

Changes of cerebrospinal fluid Aβ42, t-tau, and p-tau in Parkinson's disease patients with cognitive impairment relative to those with normal cognition: a meta-analysis

Xiaohui Hu et al.

NEUROLOGICAL SCIENCES (2017)

Add to Collection

Article Neurosciences

Interference of α-Synuclein Uptake by Monomeric β-Amyloid1-40 and Potential Core Acting Site of the Interference

Daniel K. Y. Chan et al.

NEUROTOXICITY RESEARCH (2016)

Add to Collection

Review Clinical Neurology

Parkinson's disease dementia: a neural networks perspective

James Gratwicke et al.

BRAIN (2015)

Add to Collection

Article Clinical Neurology

Amyloid deposition in Parkinson's disease and cognitive impairment: A systematic review

Myria Petrou et al.

MOVEMENT DISORDERS (2015)

Add to Collection

Review Clinical Neurology

MDS clinical diagnostic criteria for Parkinson's disease

Ronald B. Postuma et al.

MOVEMENT DISORDERS (2015)

Add to Collection

Review Neurosciences

Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker

Zhihui Yang et al.

TRENDS IN NEUROSCIENCES (2015)

Add to Collection

Article Geriatrics & Gerontology

Cognitive Impairment in Parkinson Disease: Impact on Quality of Life, Disability, and Caregiver Burden

Iracema Leroi et al.

JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY (2012)

Add to Collection

Article Clinical Neurology

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines

Irene Litvan et al.

MOVEMENT DISORDERS (2012)

Add to Collection

Article Clinical Neurology

A Validation Study of the Japanese Version of the Addenbrooke's Cognitive Examination-Revised

Kelssy Hitomi dos Santos Kawata et al.

DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA (2012)

Add to Collection

Review Clinical Neurology

Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson's Disease

Claire L. Tomlinson et al.

MOVEMENT DISORDERS (2010)

Add to Collection

Article Clinical Neurology

Parkinson Disease With Dementia Comparing Patients With and Without Alzheimer Pathology

Marwan N. Sabbagh et al.

ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2009)

Add to Collection

Article Clinical Neurology

Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale Presentation and Clinimetric Testing Results

Christopher G. Goetz et al.

MOVEMENT DISORDERS (2008)

Add to Collection

Review Clinical Neurology

Clinical diagnostic criteria for dementia associated with Parkinson's disease

Murat Emre et al.

MOVEMENT DISORDERS (2007)

Add to Collection

Article Geriatrics & Gerontology

The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening

Eneida Mioshi et al.

INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2006)

Add to Collection

Review Clinical Neurology

A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance

Paolo Calabresi et al.

LANCET NEUROLOGY (2006)

Add to Collection

Article Geriatrics & Gerontology

The montreal cognitive assessment, MoCA:: A brief screening tool for mild cognitive impairment

ZS Nasreddine et al.

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2005)

Add to Collection

Article Clinical Neurology

The FAB - A frontal assessment battery at bedside

B Dubois et al.

NEUROLOGY (2000)

Add to Collection

Article Clinical Neurology

Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease

HI Hurtig et al.

NEUROLOGY (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.